We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Belluscura Plc | BELL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.25 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 25/10/2023 11:45 by hedgehog 100 Date Time Source Headline Symbol Company25/10/2023 07:00 UK Regulatory (RNS & others) Belluscura PLC Statement regarding possible offer LSE:BELL Belluscura Plc "Statement regarding possible offer for TMT Acquisition plc The boards of Belluscura plc (AIM: BELL) and TMT Acquisition plc ("TMT Acquisition") announced on 3 October 2023 that they had reached agreement on the key terms of a possible share for share offer for TMT Acquisition by Belluscura (the "Possible Offer"). Both companies have completed confirmatory due diligence and expect to be in a position to announce a firm offer shortly, and by not later than 5.00 p.m. on 31 October 2023. The terms of the Possible Offer have been revised and will now comprise the issuance of 3 new ordinary shares of Belluscura ("Belluscura Shares") in exchange for every 4 ordinary shares of TMT Acquisition ("TMT Acquisition Shares") equaling 20,625,000 Belluscura Shares (the "Revised Exchange Ratio"). The Revised Exchange Ratio would imply a valuation of 20.25 pence for each TMT Acquisition Share based upon the Belluscura closing middle market price of 27.0p on 24 October 2023, being the last practicable date prior to the announcement of the Revised Possible Offer (the "Revised Possible Offer Terms"). Accordingly, on the basis of the Revised Exchange Ratio, the Revised Possible Offer Terms will imply a total valuation of GBP5.57 million for TMT Acquisition, representing a premium of approximately: -- 19.12 % to the closing price of a TMT Acquisition Share of 17.0p on 24 October 2023, being the last business day before this announcement; and -- 14.30 % to the TMT Acquisition three-month volume weighted average price for the period ending 24 October 2023, being the last business day before this announcement. The independent director of TMT Acquisition, Paul Tuson (the "Independent TMT Acquisition Director"), has reconfirmed to Belluscura that, should a firm offer be made on the Revised Possible Offer Terms (as outlined above), the Independent TMT Acquisition Director is minded to recommend it to TMT Acquisition shareholders. Any announcement by Belluscura of a firm intention to make an offer for TMT Acquisition remains subject to the satisfaction or waiver (by Belluscura) of a number of customary pre-conditions, including, inter alia, completion of confirmatory due diligence, agreement of the detailed terms of the Possible Offer and a recommendation from the Independent TMT Acquisition Director. ..." So, improved terms for TMTA, to reflect the dip in the BELL share price - these were probably necessary to get the deal approved by TMTA. Previously, the provisional arrangement was 15 BELL shares for every 22 TMTA shares; now the intended arrangement will equate to 16.5 BELL shares for every 22 TMTA shares: i.e. TMTA shareholders should get 10% more than previously. The current BELL share price is 26.5p (25p - 28p): which based on 3 BELL shares for every 4 TMTA shares equates to 19.875p (18.75p - 21p) TMTA. But TMTA is currently 17p (16p - 18p), giving a reasonably attractive arbitrage opportunity here again, especially if you can get inside the headline spreads. |
Posted at 24/10/2023 14:04 by hedgehog 100 24/10/2023 07:05 UK Regulatory (RNS & others) Belluscura PLC Belluscura Launches Direct to Consumer Program LSE:BELL Belluscura Plc"LONDON, U.K., PLANO, TX, U.S. and SHENZHEN, CHINA (24 October 2023). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that early results on the two-month-old direct to consumer program have exceeded the Board's initial expectations. The Company has introduced a three-prong direct sales, leasing and short-term rental program for its established X-PLOR (R) device that has been well received by customers. Recognising a significant need and opportunity to provide portable oxygen concentrators to customers not previously served by durable medical equipment companies, the Company designed a program intended to capture a meaningful underserved population of people suffering from lung disease. The Company sees this program expanding significantly with the launch of the DISCOV-R (TM) portable oxygen concentrator. Bob Fary, Senior Vice President Sales and Marketing Belluscura plc, commented: "I am very excited about the new direct-to consumer sales program. We have identified a potentially significant sales opportunity that not only benefits the Company, but underrepresented patients as well." ..." So BELL have again exceeded expectations, showing that the swift appointment of distributors in 2021 was no flash in the pan. And it looks like they've identified a real gap in the market here, and could really clean up big time. |
Posted at 16/10/2023 14:02 by hedgehog 100 I'd also be interested in your views as to why TMTA directors Harry Hyman & Jonathan Satchell, both of whom have a billion-pound track record, are investing here, via their TMTA vehicle?For the last couple of years they will doubtless have had a good view of many potential UK tech floats, but have decided that BELL is the best opportunity available to TMTA. Their success, judgement, and business acumen should be respected. And they will have had a very good look at BELL's prospects, and its chances of delivery. The fact that Jonathan Satchell is coming on board here as a director is another major positive, and looks particularly exciting for the app and software side of BELL. It could be that J.S. is viewing BELL as a chance to replicate his success with Learning Technologies Group (LTG), which he 40-bagged from its RTO price of 5.88p/share to its high of about 236p. In addition, their 'pulling power' in attracting more institutional investors into BELL could be very positive for BELL's s.p. Those institutional investors who backed TMTA at 20p should be keen to add to their positions in BELL, and at a premium to their previous investments at 20p in TMTA (which equates to 29.33p per BELL share). |
Posted at 16/10/2023 13:42 by hedgehog 100 A key to success in investment is identifying turning points, in time to benefit from them as fully as possible.Slippage in business and investment is par for the course, especially in the current challenged global economy. So you have to distinguish normal business slippage, which to a degree can be expected, from bad companies just stringing investors along. Regarding the expectations at IPO. Appointment of US distributors was expected to start from 1st. July 2021 onwards, but actually the first one was appointed on 23rd. June, with three more following by the end of July. That first one was only a week ahead of the earliest expectations, but it still bodes very well for the future - for the company's ability to deliver on it's plan. With small company shares, delays and missed timetables are commonplace, whereas delivering ahead of schedule is pretty rare. 28/05/2021 07:00 UK Regulatory (RNS & others) Belluscura PLC Admission to trading on AIM; First Day of Dealings LSE:BELL Belluscura Plc " ... Belluscura plans to launch the X-PLO2R shortly and the X-PLO2R CX and X-PLO2R DX within the next 12 months. The Company has a manufacturing agreement to produce the products in the USA. Following a soft launch, the Company plans to appoint distributors in the US to give US-wide coverage; this is expected to occur in the second half of 2021 and into 2022. Belluscura will commence International Regulatory clearances during 2021 and 2022 before expanding distribution globally. Following launch in the US, the Company intends, in due course, to pursue commercialisation in the UK, EU, Japan, South Asia, Australia, South America and Latin America. ..." 23/06/2021 07:00 RNS Non-Regulatory Belluscura PLC First US Distribution Agreement LSE:BELL Belluscura Plc |
Posted at 15/10/2023 15:40 by hedgehog 100 You'd be hard pushed to find more confident-sounding outlook statements than BELL's recently.But it's not just words: it's backed up by a new $55M. royalty deal, and attracting the investment of TMTA's billion-pound track record 'shellmeisters'. And now with the requisite funding arranged, the company is all set to really start motoring. BELL's market cap. could certainly be hundreds of millions within a few years I would think, and indeed this share looks to have excellent ten-bagger potential from its current level of just 27p. 13/09/2023 07:00 UK Regulatory (RNS & others) Belluscura PLC Half-year Report LSE:BELL Belluscura Plc " ... Post Period End : Transformational Exclusive License and Royalty Generating Agreement with InnoMax -- Belluscura exclusively licensed its proprietary technology to InnoMax in China, Hong Kong, Macau and Singapore in a deal valued at $55m in minimum royalties over the term of the license ... Adam Reynolds, Chairman of Belluscura, commented: "The team at Belluscura has made considerable headway which will enable significant momentum in the business. "We believe the signing of the g roundbreaking Exclusive License and Royalty Generating Agreement with InnoMax, an affiliate of the world's leading electronics manufacturing company, will be transformational for the Group. "Belluscura is, therefore, well positioned to achieve its expectations in the coming years. The initial response from the market in the Group's products is hugely positive and, as we scale up the business, we expect substantial growth over the coming years, leaving the Board highly confident in Belluscura's future." ... Outlook We have made considerable progress with building the foundations for significant growth in the coming years. Trading since the period end is in line with our expectations for the full year, which is significantly second half weighted. Demand for X-PLOR (R), which is predominantly a Direct-to-Consumer unit, is growing, and we expect that our affiliation with GoodRX, and our own direct sales will lead to significantly higher Gross Margins as we utilise the Company's previously high inventory levels. The demand and orders already received for DISCOV-R are very exciting, and we believe the signing of the g roundbreaking Exclusive License and Royalty Generating Agreement with InnoMax, an affiliate of the world's leading electronics manufacturing company, will be transformational for the Group. The Company is well positioned to deliver substantial growth in the coming years, and we look forward to the future with confidence. ..." |
Posted at 14/10/2023 20:48 by hedgehog 100 "BELL - onging togetherDoes the TMT Acquisition acquistion make sense? THE OAK BLOKE OCT 4, 2023 ... I’m struck by the comment that their input will be highly useful. It suggests the “App” and Software side of Belluscura has further to run as I’ve theorised in past articles. ..." This dovetails with part of the "Future Opportunities" section of the Belluscura AIM admission document, 24 May 2021:- "Future Opportunities Biometric Drug & Device Data The Directors believe that following the launches of the products above, there is a significant opportunity to enhance these devices by collecting and collating Smart data. Through the integration of biometric data from smart devices, Belluscura would be able to collate valuable clinical data to aid patients’ clinicians to better understand the use of the device and in turn allow clinicians to better assess their patients’ changing needs. Integration possibilities include: GPS Smart Watch Activity, movement, location, altitude, heart rate, stress levels, sleep patterns Smart Pulse Oximeter Blood saturation - SaO2 Smart Inhaler Providing medication information X-PLO2R (with Bluetooth) Oxygen flow setting and breathing rate Collecting this information through a Belluscura COPD App the Company should be able to provide a fuller overall picture of a patient’s circumstances, activity and functionality to the clinician, making the X-PLO2R range of products a more valuable proposition. Devices beyond X-PLO2R Belluscura also has three further products in development, which utilise the same technology as the X-PLO2R but for larger units: HO2ME HO2ME is a prototype of the X-PLO2R but is stationary and for home use. HO2ME is expected to be able to deliver 5-10L of continuous oxygen and is intended for Stage 4 COPD patients. VENTO2LAT-R A non-invasive portable ventilator. ECMO2 Device Extra-Corporeal Membrane Oxygen (“ECMO”) has for many years been used for patients with life-threatening hypoxaemia and hypercarbia. Positive outcomes by patients who suffered from SARS or Swine Flu has resulted in ECMO becoming a recommended treatment for patients with severe acute respiratory distress syndrome. Belluscura is developing a portable ECMO product (“ECMO2” |
Posted at 07/10/2023 10:52 by hedgehog 100 These are what look to be three BELL-TMTA arbitrage trades on Thursday:-Belluscura (BELL) Date Time Trade Prc Volume Buy/Sell Bid Ask Value 05-Oct-23 12:31:16 32.7501 7,500 Sell* 32.00 38.00 2,456 O 05-Oct-23 10:39:32 32.722 7,377 Sell* 32.00 38.00 2,414 O 05-Oct-23 10:38:50 33.00 30,000 Sell* 32.00 38.00 9,900 O TMT Acquisition (TMTA) Date Time Trade Prc Volume Buy/Sell Bid Ask Value 05-Oct-23 12:31:55 20.40 12,000 Buy* 19.00 21.00 2,448 O 05-Oct-23 10:40:31 19.80 50,198 Unknown* 19.00 20.00 9,939 O 05-Oct-23 10:41:02 19.80 11,464 Buy* 19.00 20.00 2,270 O The seller of the 30,000 BELL trade looks to have bought 50,198 TMTA with the proceeds. On the basis that TMTA shareholders will receive 15 BELL shares for every 22 TMTA shares, this trader should receive 34,225 BELL shares for these 50,198 TMTA shares. I.e. a likely free 4,225 BELL shares: worth £1,394 at the current BELL mid price of 33p. And if Jonathan Satchell 40-bags BELL, as he did with Learning Technologies Group (LTG), 4,225 BELL shares could be worth over £50K. Which wouldn't be a bad return for what looks to have been an essentially risk-free arbitrage trade! The BELL-TMTA arbitrage benefit has now narrowed, but the window of opportunity is still open. Logically though you would expect it to narrow further and close, due to further arbitrage trading, & investors buying TMTA as a likely discounted route into BELL. |
Posted at 04/10/2023 16:40 by hedgehog 100 Closing s.p.s today:-BELL 35p (32p - 38p). TMTA 19.5p (19p - 20p). On the basis that TMTA shareholders will receive 15 BELL shares for every 22 TMTA shares, the current TMTA offer price of 20p/share equates to a BELL offer price of 29.33p/share, i.e. 22.82% less than the current BELL offer price of 38p. So TMTA is potentially a significantly cheaper way into BELL at the moment than buying BELL shares directly. Stuffee, Why don't you feel that TMTA shareholders will be natural shareholders for BELL? The whole point of buying a shell like TMTA is that it's potentially a cheaper route into a non-shell company; shell investors neither expect nor want it to remain a shell forever. And TMTA was set up specifically to invest into a tech company like BELL:- "TMT Acquisition was incorporated in March 2021. The Company has been formed to pursue opportunities to acquire businesses in the technology, media and telecom sector (“TMT sector”)." |
Posted at 30/8/2023 09:13 by buywell3 Ref the financial impact of this RNS --- buywell opines:Under the terms of the ten-year Agreement, effective from 1 October 2023, Belluscura is to receive annually increasing minimum cumulative royalties over the term of the Agreement. In addition to receiving royalties on licensed products (subject to annually increasing minimum amounts), Belluscura will receive a share of the net profits on sales of accessories. The Agreement will be exclusive for a minimum of 5 years, though if minimum sales quantities are not achieved, Belluscura and InnoMax can mutually agree to grant InnoMax a non-exclusive license for the remainder of the term. Minimum cumulative royalties over the term of the Agreement will therefore range from $27.5m if the license is converted to non-exclusive from year 6 and up to $55m in cumulative royalties if the license remains exclusive for the entire term. -------------------- buywell adds_ There are just shy of 135.67 Million Belluscura shares in issue according to FT $27.5 Million and $55 Million as stated in the RNS equate to 16p or 32p a BELL share On top of this BELL already have a US order for 6,500 in the bag Today's announcement follows news earlier this month that Belluscura has received purchase orders for over 6,500 of its DISCOV-R portable device for the US market, which the Company plans a controlled roll out of in Q3 and into 2024 to meet growing demand for the device amid substantial interest from medical device distributors, retailers, patients and durable medical equipment providers, among others. buywell adds That US order alone should equate to around $12M to 13M of revenue and looks set to rise in America due to increasing interest in the Belluscura products which have the NOMAD App -------------------- China is a much BIGGER market than the US for oxygen concentrators From the RNS Bob Rauker, Chief Executive Officer, Belluscura plc, commented: "I am very excited to build and strengthen our relationship with InnoMax. An estimated 100 million people suffer from COPD in China alone, approximately six times the number of patients in the US, demonstrating the need for oxygen therapy in China and associated Territories. This agreement provides the basis for an extremely financially beneficial partnership for both companies as we jointly broaden the reach of Belluscura's next-generation technology." -------------------- All of the above is to date , looking at the COPD market for the Belluscura products As yet the Long Covid and Sleep Apnea markets (using a Belluscura product as a CPAP) have not IMO been factored in IMO these additional markets combined could be larger than the COPD market as the lung/heart/organ damage and effects of Long Covid are further realized -------------------- Soon there will be approval news from the EU for Belluscura devices Existing BIG named EU Health Service providers of oxygen concentrators are currently talking to Belluscura to distribute their products More news on that also coming soon dyor imo Tekcapital (TEK) owns 15,138,767 shares of Belluscura plc (BELL) 11.16% |
Posted at 17/8/2023 08:13 by buywell3 17 August 2023Portfolio Companies Update Tekcapital Plc (AIM: TEK), the UK intellectual property investment group is pleased to provide a summary of latest developments across certain of its portfolio companies. Belluscura Belluscura plc ("Belluscura" AIM: BELL), announced on 16 August 2023 it has received purchase orders for over 6,500 of its next-generation DISCOV-R portable oxygen concentrator. This represents approximately US$15 million of potential revenue to Belluscura plc, as estimated by its management team. The recent purchase orders follow the signing of several distribution agreements with medical device distributors and other home healthcare providers, including a distribution agreement with a division of McKesson, one of the largest distributors of pharmaceuticals and medical devices in North America, earlier this month and a marketing agreement with GoodRx®, a leading digital healthcare platform, in February 2023. Belluscura has received multiple additional requests from leading oxygen homecare providers in the US to distribute the DISCOV-R. Tekcapital owns 15,138,767 shares of Belluscura plc (11.16%). -------------------- buywell notes that Tekcapital still is a Major Shareholder in Belluscura , holding 15,138,767 shares of Belluscura plc (11.16%). buywell hopes that Tekcapital can keep theses shares in Belluscura as they stage a recovery in share price based upon the coming surge of sales referred to in yesterdays Belluscura RNS and enhanced Telehealth software in the form of NOMAD its patented App , providing the necessary data for monitoring and control purposes by the remotely located patient Healthcare provider The news imo underpinned what the Belluscura CFO recently said in video ie: " Belluscura should be cash positive in the first half of 2024 " The chart of TEK IMO has been driven by that of BELL ---- hence buywell hopes and believes a recovery in the Belluscura share price chart --- which we are now seeing start to happen after the cash raise at 25p , could now drag the TEK share price chart back north. Note the current divergence caused by the surge in Belluscura SP plus As Belluscura starts to win market share from other existing oxygen concentrator providers , and sales into China and APAC begin in 2024 Belluscura with their disruptive patented technology will become a thorn in bigger sides Sooner rather than later one of them will want to remove that thorn dyor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
